Table 1.
Clinical and tumor-related characteristics of the study population (N = 244)
| Characteristics | No. of patients | % 1 | |
|---|---|---|---|
|
Patient characteristics |
|
|
|
|
Age (Years), mean±SD (range) |
58,2±13,3 (29-91) |
|
|
|
Weight (Kg), median (interquartile range) |
67 (60-76) |
|
|
|
Height (cm), median (interquartile range) |
160 (154-163) |
|
|
|
BMI (Kg/m
2
), median (interquartile range) |
26,7 (23,5-30,44) |
|
|
|
Menopausal status (yes) |
|
126 |
65,6 |
|
Gestation (yes) |
|
182 |
90,54 |
|
Breast-feeding (yes) |
|
146 |
79,3 |
|
Oral contraception/HT (yes) |
|
96 |
55,6 |
|
Family history of BC♯ (yes) |
|
56 |
27,5 |
|
TC (mg/dL), median (interquartile range) |
209,5 (191-231) |
|
|
|
HDL-C (mg/dL), median (interquartile range) |
53 (46-60) |
|
|
|
LDL-C (mg/dL), median (interquartile range) |
128 (110-153) |
|
|
|
Triglycerides (mg/dL), median (interquartile range) |
94 (74,5-126) |
|
|
|
Tumor characteristics
2
|
|
|
|
|
Histological type |
IDC |
244 |
100 |
|
Tumor size (mm), median (interquartile range) |
21 (14-30) |
|
|
|
Tumor stage (T) |
T1, ≤ 2 cm |
122 |
50 |
| |
T2, 2-5 cm |
115 |
47,2 |
| |
T3, >5 cm |
7 |
2,8 |
|
Tumor differentiation grade |
G1 |
27 |
12,4 |
| |
G2 |
134 |
61,5 |
| |
G3 |
57 |
26,2 |
|
Immunohistochemical subtypes |
ER/PR positive |
204 |
83,9 |
| |
Triple negative |
23 |
9,5 |
| |
HER 2 Type |
16 |
6,6 |
|
LVI positive |
|
61 |
29,2 |
|
Nodal stage (N) |
N0 |
137 |
56,9 |
| |
N1, 1-3 LN+ |
72 |
29,9 |
| |
N2, 4-9 LN+ |
18 |
7,47 |
| |
N3, ≥10 LN+ |
14 |
5,8 |
|
Clinical stage |
I |
84 |
34,4 |
| |
II |
125 |
51,3 |
| |
III |
35 |
14,3 |
| Bilaterality (yes) | 10 | 4,1 |
¹Frequency of known cases.
2Tumor characteristics based on The American Joint Committee on Cancer [58].
Histological type of breast cancer (IDC is presently named invasive carcinoma, NOS); Tumor Stage T of TNM Classification (T1≤2cm; T2:2-5cm; T3>5 cm); Tumor Differentiation Grade of Nothingham Histologic Score (G1, G2, G3); Immunohistochemical subtypes [Luminal A and B (ER/PR positive); Triple negative (ER/PR negative and Her2-neu negative); HER2 Type (ER/PR negative and Her2-neu positive)]; Pathological axillar Nodal Stage of TNM Classification (N0: no metastatic LN; N1: 1-3 metastatic LN; N2:4-9 metastatic lymph nodes; N3≥10 metastatic lymph nodes); Clinical Stage or Prognostic Stages Groups of American Joint Committee on Cancer (I, II, III,IV).
HT: Hormonal Therapy; BC: Breast Cancer; BMI: Body Mass Index; HT: Hormonal Therapy; TC: Total Cholesterol; LDL-C: Low Density Lipoprotein; HDL-C: High Density Lipoprotein IDC: Invasive Ductal Carcinoma; ER: Estrogen Receptor; PR: Progesterone Receptor; LVI: Lymphovascular Invasion; LN: Lymph Nodes.